Announcements Trials
Browse Landscape

Phase

Phase 1 4Phase 2 2Phase NA 1Phase EARLY_PHASE1 1Phase 4 1Phase 2/3 1Phase 1/2 1

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 5Lymphoid 3Gastrointestinal 3Plasma cell 2NET 2Endocrine 2Breast 2Other hematologic neoplasm 1Head & Neck 1Gynecologic 1CNS 1

Conditions

Neuroendocrine Tumors 2

Interventions

Everolimus 27pembrolizumab 25Temozolomide 24lutetium Lu 177 dotatate 22Nivolumab 18Magnetic Resonance Spectroscopy 18lenvatinib 17cabozantinib 17Cisplatin 16Sunitinib 15Capecitabine 14Bevacizumab 14Specimen Handling 12Sorafenib 12trametinib 10Ipilimumab 10Etoposide 10pasireotide 9dabrafenib 9Paclitaxel 9Carboplatin 8pazopanib 7lanreotide 7Octreotide 7Fluorodeoxyglucose F18 7anlotinib 6Irinotecan 6Injections 6Doxorubicin 6surufatinib 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Positron Emission Tomography Computed Tomography × Endocrine × Clear all
NCT03271281 2022-06-30

PET/CT Imaging of Angiogenesis in Patients With Neuroendocrine Tumors Using 68Ga-NODAGA-E[c(RGDyK)]2

Rigshospitalet, Denmark

Phase 2 Completed
113 enrolled
EndocrineNET

Neuroendocrine Tumors

NCT03278275 2022-06-30

PET/CT Imaging of uPAR-expression in Patients With Neuroendocrine Tumors Using 68Ga-NOTA-AE105

Rigshospitalet, Denmark

Phase 2 Completed
116 enrolled
EndocrineNET

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡